This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class A at inception (02/03/2009). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.
Patient Opportunity Trust returns as of month ending 09/30/2024
Patient Opportunity Trust returns as of quarter ending 09/30/2024
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.
Class A Expense Ratio
Gross: 2.12%
Net: 2.11%
This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class C at inception (12/30/1999). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.
Patient Opportunity Trust returns as of month ending 09/30/2024
Patient Opportunity Trust returns as of quarter ending 09/30/2024
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.
Class C Expense Ratio
Gross: 2.88%
Net: 2.87%
This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class FI at inception (02/13/2004). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.
Patient Opportunity Trust returns as of month ending 09/30/2024
Patient Opportunity Trust returns as of quarter ending 09/30/2024
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.
Class FI Expense Ratio
Gross: 2.17%
Net: 2.16%
This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class I at inception (06/26/2000). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.
Patient Opportunity Trust returns as of month ending 09/30/2024
Patient Opportunity Trust returns as of quarter ending 09/30/2024
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.
Class I Expense Ratio
Gross: 1.88%
Net: 1.85%
This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class R at inception (12/28/2006). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.
Patient Opportunity Trust returns as of month ending 09/30/2024
Patient Opportunity Trust returns as of quarter ending 09/30/2024
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.
Class R Expense Ratio
Gross: 2.38%
Net: 2.37%
This chart illustrates the performance of a hypothetical $10,000 investment made in the Funds Class IS at inception (08/22/2018). Assumes reinvestment of dividends and capital gains, but does not reflect the effect of any applicable sales charge or redemption fees. This chart does not imply any future performance. Click and drag on line chart to zoom in to a specific time range.
Patient Opportunity Trust returns as of month ending 09/30/2024
Patient Opportunity Trust returns as of quarter ending 09/30/2024
Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Fund performance current to most recent month-end may be lower or higher than the performance quoted. Patient Capital Management has agreed to waive fees and/or reimburse operating expenses through April 30, 2025, so that such annual operating expenses will not exceed 0.88%, subject to recapture as described below. Performance data shown with load reflects the Class A maximum sales charge of 5.75% and Class C maximum deferred sales charge (MDSC) of 1.00%. Performance for the Class A and C shares shown without load does not reflect the deduction of the sales load or MDSC. If reflected, total return would be reduced.
Class IS Expense Ratio
Gross: 1.78%
Net: 1.77%